Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Last trade$29.09
Day change-$1.07 (-3.55%)
Day range$28.45 – $30.58
Volume1,219,529
Market cap$4.13B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.13B
Price / earnings
—
Price / book
4.27×
Price / sales
—
EV / sales
—
EV / EBITDA
-15.44×
Profitability
Earnings per share
-$2.47
Return on assets
-31.41%
Return on equity
-34.86%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.04×
Current ratio
15.53×
Quick ratio
15.53×
Cash ratio
3.56×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$191.36M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DFTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$0
$0
$0
Cost of revenue
$0
$0
$0
Gross profit
$0
$0
$0
Selling, general and administrative
$26.14M
$26.41M
$17.74M
Research and development
$46.14M
$48.67M
$41.48M
Total operating expenses
$72.28M
$75.08M
$59.22M
Operating income
-$72.28M
-$75.08M
-$59.22M
Interest expense
-$1.15M
-$1.23M
-$1.25M
Income before taxes
-$50.96M
-$158.99M
-$77.1M
Income taxes
$0
$0
$0
Net income
-$50.96M
-$158.99M
-$77.1M
Net income attributable to common shareholders
-$50.96M
-$158.99M
-$77.1M
EBITDA
-$72.28M
-$75.08M
-$59.22M
Basic earnings per share
-$0.37
-$1.44
-$0.71
Diluted earnings per share
-$0.46
-$1.44
-$0.71
Recent news
Company coverage with links to the original publishers.
Definium Therapeutics announced positive Phase 3 clinical trial results for its lead psychiatric drug DT120 in generalized anxiety disorder and major depressive disorder, with plans to file for regulatory approval in the first half of 2027. The company holds $1.05 billion in cash to fund operations through 2030 and showed early efficacy signals for pipeline expansion into autism spectrum disorder with DT402.
Definium Therapeutics announced positive Phase III results for DT120 ODT in generalized anxiety disorder, with the Panorama study meeting primary and key secondary endpoints. The treatment showed a 5.1-point placebo-adjusted benefit in HAM-A scores at Week 12 with rapid effects by day 2. The company plans an FDA pre-NDA meeting in Q4 2026 and NDA filing in H1 2027, with DT120 also advancing in major depressive disorder and posttraumatic stress disorder trials.
Trump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with high upside targets, these remain speculative investments with substantial risks.
President Trump signed an executive order to fast-track FDA approval of psychedelic treatments for mental disorders, reducing review times from 6-10 months to 1-2 months. The order also allocates $50 million for private sector research. Three biotech companies with breakthrough therapy designations saw significant stock gains following the announcement.
Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.